MAGE: the spell is broken.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 22068655.
- Also identified by DOI 10.1158/1078-0432.CCR-11-2302.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The success of immunotherapy in Hodgkin lymphoma is hampered partly by limited expression of tumor-specific antigens in the malignant cells. One strategy to increase tumor immunogenicity may be to enhance the expression of Hodgkin lymphoma-specific antigens such as MAGE-A4 using epigenetic-modifying drugs in combination with cancer testis antigen-specific immunotherapy.
Medical subject headings
- Antigens, Neoplasm
- Antimetabolites, Antineoplastic
- Azacitidine
- Hodgkin Disease
- Immunotherapy, Adoptive
- Neoplasm Proteins
- T-Lymphocytes